Hoyoung Huh

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Carlos, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Jennifer Woo, attorney-in-fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Hoyoung Huh

Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
4,695,854
Estimated value
$5,259,356
Report date
20 Mar 2025
Price
$1.12
Ownership
Direct
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
Pre-Funded Warrants to purchase ADRs
Shares / value
3,093,293
Estimated value
$1,249,999
Report date
16 Dec 2025
Price
$0.4041
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
Series A Warrants (Right to Buy)
Shares / value
892,857
Estimated value
$1,000,000
Report date
06 Mar 2025
Price
$1.12
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
Series B Warrants (Right to Buy)
Shares / value
892,857
Estimated value
$1,000,000
Report date
06 Mar 2025
Price
$1.12
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
109,457
Estimated value
$122,592
Report date
20 Mar 2025
Price
$1.12
Ownership
Hannol Ventures LLC
Form 4 holding Director

PLIANT THERAPEUTICS, INC.

Security class
Common Stock (Right to Buy)
Shares / value
30,000
Estimated value
$55,669
Report date
05 Jun 2025
Price
$2.08
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Peak Bio, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
14 Nov 2024
Price
$0.2650
Ownership
Direct
Form 4 holding Director, 10%+ Owner

Peak Bio, Inc.

Security class
Common Stock
Shares / value
0
Estimated value
$0
Report date
14 Nov 2024
Price
$0.2650
Ownership
Indirect
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
Warrants to purchase ADRs
Shares / value
3,093,293
Estimated value
Report date
16 Dec 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
Warrants to purchase American Depositary Shares ("ADRs")
Shares / value
618,658
Estimated value
Report date
16 Dec 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Akari Therapeutics Plc

Security class
Stock Option (Right to Buy)
Shares / value
225,000
Estimated value
Report date
20 Mar 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Peak Bio, Inc.

Security class
Convertible Notes
Shares / value
0
Estimated value
Report date
14 Nov 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Peak Bio, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
14 Nov 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Peak Bio, Inc.

Security class
Warrant (Right to Purchase)
Shares / value
0
Estimated value
Report date
14 Nov 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Hoyoung Huh

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .